Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Bioorg Med Chem. 2013 Aug 13;21(21):10.1016/j.bmc.2013.08.006. doi: 10.1016/j.bmc.2013.08.006

Table 3.

In vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidine prodrugs in the STIB900 mouse model.a

Code Dosage (po, mg/kg)c Cures d Survival (days)e
2b(2a) 100 0/4 50
2c(2a) 25 4/4 >60
10 4/4 >60
3c(3a) 25 4/4 >60
4c(4a) 25 2/4 >42
11(10) 25 4/4 >60
10 0/4 22.5
12(10) 25 3/4 >53.5
10 3/4 >56.5
20a(19a) 25 2/4 >45.75
21a(19a) 25 3/4 >57.5
10 1/4 >49
20b(19b) 25 2/4 >50
21b(19b) 25 2/4 >50
24a(23a) 25 0/4 23.75
25a(23a) 25 2/4 >38.75
24b(23b) 25 4/4 >60
10 1/4 >33.75
25b(23b) 25 1/4 >43.25
a

See Refs. 5 and 18 for details of STIB900 mouse model.

b

Code for parent of prodrug in parenthesis.

c

Daily dosage was administered for 4 days.

d

Number of mice that survive and are parasite free for 60 days.

e

Average days of survival; untreated control expires between day 7 and 9 post-infection.